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Effects of magnanimous therapy on emotional, psychosomatic 
and immune functions of lung cancer patients 
Abstract 
This study was a randomised controlled study on the effects of the individual computer 
magnanimous therapy and group computer magnanimous therapy on emotional, psychosomatic 
and immune function among advanced lung cancer patients. Patients were examined at baseline 
and 2 weeks later using the Psychosomatic Status Scale for Cancer Patients, Hospital Anxiety 
Depression Scale and IgA, IgG, IgM and natural killer cell functions. The results showed that 
individual computer magnanimous therapy and group computer magnanimous therapy were 
beneficial for advanced lung cancer patients in improving depression, anxiety, psychosomatic 
status and immune functions. The improvements of immune functions may be related to the 
improvements of the participants’ emotional and psychosocial status. 
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Lung cancer has the highest incidence and mortality among all cancers. As a result, in recent 
years there have been calls for an effective and efficient approach to treatment, which combines 
physical and psychological techniques (Chang et al., 2012; Ferlay et al., 2010). Although some 
research indicates that cognitive behavioural therapy (CBT) appears not to be clinically 
effective for treatment of depression in people with advanced cancer (Lepore and Coyne, 
2006; Serfaty et al., 2019), it is believed that psychological input remains an important part of 
the combined approach to lung cancer treatments (Huang, 2018, 2019). 
Psychological distress, caused by poor prognosis, the severity of symptoms and the side-
effects of treatments, has been found to be persistent in lung cancer patients throughout the 
clinical course of illness (Ftanou et al., 2019). For example, research shows that emotional 
distress is significantly correlated with poorer prognosis of cancers, including lung cancer 
(GBD 2015 Risk Factors Collaborators, 2016; Pozo et al., 2014). Although it has not been 
universally recognised, some studies (including this research) have suggested that those who 
develop cancer may be more likely to suppress negative emotions than those who do not 
(Baltrusch, 1988; Huang et al., 2009). For instance, people with a Type-C or Type-T personality, 
namely the Cancer- or Tumour-prone personality, are characterised by their abnormal inhibition 
of emotions and inability to express anger. These psychological responses to emotions have 
been implicated as factors that may influence the development of cancer, and depression is 
linked to a significantly reduced chance of survival following diagnosis (Deimling et al., 
2006; Watson et al., 1999). Moreover, psychologists specialising in psychoneuro-immunology 
(PNI) suggest that a patient’s emotional state affects their immune system. In case of cancer, it 
is possible that positive emotional responses may help generate specialised ‘killer’ cells that 
help control the size and spread of cancerous tumours. Conversely, negative emotions may 
suppress the ability of those cells to fight against tumours (Boggero and Segerstrom, 
2016; Evans et al., 2000; Schedlowski, 1999). 
Thus, reducing levels of depression and encouraging expression of suppressed negative 
emotions (e.g. anger, worry, fear and anxiety) may improve immune function and increase 
chances of survival. Liu (2010) and Lu et al.’s (2012) studies on the psychological 
characteristics of long-term cancer survivors with sound psychological, physical and social 
quality of life found that these survivors had some common psychological characteristics. These 
characteristics included being or becoming magnanimous and open-minded; having a good 
mental health status and lower cancer- or tumour-prone personality level; being able to accept 
reality and to think positively and properly about the disease state; and being optimistic and 
peaceful. In their later studies on the cancer survivors, Huang (2019) employed magnanimous 
therapy (MT) to help the cancer survivors achieve high magnanimous mental status so as to 
more effectively cope with depressive symptoms and reduce suppressed negative emotions. 
As a new and original psychotherapy, MT focuses on helping people develop insights into 
and understanding of life (Huang, 2018). It helps individuals restructure their cognitive habits 
and modify their behavioural mode to develop traits related to being magnanimous and open-
minded, enterprising and positive, and optimistic and harmonious. The development of these 
traits can lead to a peaceful and relaxed state: spiritually, psychologically and physically. 
Clients can then apply all of these new-found traits and skills to their problem-solving in daily 
life. Consequently, the magnanimous psycho-behavioural mode could be instilled as a part of 
the clients’ life (for details of underlying theoretical frameworks of MT, see Huang, 2018). 
Research has shown that MT is effective in improving advanced lung cancer patients’ coping, 
adjustment and living functions. For example, a group of Chinese researchers found that both 
individual computer magnanimous therapy (ICMT) and group computer magnanimous therapy 
(GCMT) reduced lung cancer patients’ anxious and depressive symptoms, increased their 
psychological coping and adjustment, and thus improved the quality of life for patients with 
breast cancer, depression and hypertension (Huang, 2019; Li, 2012; Lu, 2013; Qian, 
2011; Yang et al., 2013). 
However, the effects of ICMT and GCMT on the emotional, psychosomatic and immune 
efficacy of patients with advanced lung cancer have not yet been tested. To address the research 
gap, this study aims to (1) assess the emotional, psychosomatic and immune functions of ICMT 
and GCMT in advanced lung cancer patients; (2) compare the effects of ICMT and GCMT on 
the emotional, psychosomatic and immune efficacy and (3) explore the possible mechanism 
that produces the effect. To the authors’ knowledge, this study is the first of its kind that 
explores the relationships. 
Method 
Study design 
The study was approved by the Ethical Committee of Guangdong Pharmaceutical University 
for Clinical Medicine (Approval No.: 2013 Clinical Medicine (06)). The study was a 
randomised controlled study on the effects of ICMT and GCMT for depression and anxiety 
symptoms, psychosomatic and immune function among lung cancer patients. Patients with 
advanced lung cancer matched by demographics, diagnosis and types of oncotherapy were 
randomly assigned to either an ICMT group, a GCMT group or a control group. The ICMT and 
GCMT groups received ICMT or GCMT, respectively, in addition to routine oncotherapy and 
care, while the control group only received routine oncotherapy and care. Patients were assessed 
at baseline and 2 weeks later using the Psychosomatic Status Scale for Cancer Patients (PSSCP) 
(Chen, 2014), the Hospital Anxiety Depression Scale (HADS) (Wang, 1999a; Zigmond and 
Snaith, 1983) and the immune functions of IgA, IgG, IgM, natural killer (NK) cells were 
measured. The efficacy of ICMT and GCMT was analysed. The relationship among the changes 
of immune function and the changes of PSSCP and HADS were analysed to probe the possible 
mechanism. 
Participants 
Participants were recruited from the oncology inpatient department of two teaching hospitals in 
Guangzhou, China, during the period from September 2014 to 2017. In total, 116 patients 
participated in the study. 
The inclusion criteria were (1) diagnosed with advanced lung cancer (stage III or IV, with 
confirmed pathological diagnosis); (2) aged between 18 and 80 years; (3) personal ability to 
complete a questionnaire and to receive psychotherapy; (4) personal awareness of their cancer 
diagnosis; (5) no apparent serious intellectual impairment and mental diseases; (6) a score 
greater than 8 on the HADS and (7) consent to participate in the study and signed written 
informed consent. 
Exclusion criteria were (1) pregnant or lactating women; (2) current psychosis or history of 
a psychotic disorder; (3) substance dependence other than nicotine; (4) other acute, severe or 
unstable medical illness; (5) cognition impairment (as assessed using a Mini-Mental State 
Examination (MMSE) score of greater than 27) and (6) currently accepting immune treatments. 
The MMSE test is a 30-item questionnaire that is used extensively in clinical and research 
settings to measure cognitive impairment (Folstein et al., 1975; Wang, 1999b). It examines 
functions including registration, attention and calculation, recall, language, ability to follow 
simple commands and orientation. 
Drop-out criteria were (1) absence from the therapy sessions twice or more and (2) 
deterioration of health condition. 
The intervention 
Participants allocated to the ICMT or the GCMT groups received eight 40-minute sessions of 
ICMT or GCMT in 2 weeks, which is the typical duration of hospitalisation for lung cancer 
patients in China. Treatment was conducted by one of two trained research students using ICMT 
or GCMT software. For the patients, each session consisted of pre- and post-intervention 
assessments employing the outcome measurements and the intervention (watching a computer-
based therapy presentation and receiving interpretations of the presentation from the therapist). 
The final component of the session consisted of the patient reviewing what had been learned 
from the therapy, and as homework, identifying how that learning could be applied to problem-
solving in daily life. At the beginning of the next session, the therapist asked patients what they 
had achieved from the treatment and their personal inspirations since the previous session. Each 
set of CMT presentations consisted of eight short, philosophical stories depicted as an animation, 
accompanied by appropriate inspirations and enlightenments that help patients to achieve a 
magnanimous, enterprising, optimistic, relaxing, harmonious and peaceful state. In the ICMT 
group, the therapist used the presentation to treat one patient at a time and focused on the 
patient’s individual traits and problems. In the GCMT group, the presentation focused on 
inspiring a positive interaction effect in a group of participants facilitated by the therapist. As 
previously mentioned, the control group did not partake in any CMT presentations, but 
continued with routine oncotherapy and care. 
Outcome measurements 
Psychosomatic state was assessed using the PSSCP, which is a Chinese 16-item self-rating scale. 
The PSSCP was developed in a previous study of 515 participants measuring the psychosomatic 
status of cancer patients (Chen, 2014). The PSSCP includes four sub-scales: psychological (five 
items), somatic (four items), social (four items) and psycho-behavioural and resilience (three 
items). The psychological sub-scale measures psychological states such as mental burden, fear, 
depression and anxiety. The somatic domain screens for somatic states such as pain, nausea and 
poor sleep. The social domain sub-scale detects social states such as interpersonal 
communication and ability to work. The psycho-behavioural resilience sub-scale detects the 
ease of a participant to accept others’ suggestions and to change their mentality. Participants 
registered their responses on a 5-point Likert-type scale (ranging from 1 = ‘never’ to 
5 = ‘always’). For some items, the scale has been reversed so that a lower score indicates a 
‘better’ psychosomatic state. The scale has been deemed to have relevant content and structure 
validity. The criterion validity with the Functional Living Index-Cancer (FLIC) was −0.626 
(p < 0.01). The PSSCP is a reliable instrument; the test–retest coefficients for the four 
dimensions and the total scores were from 0.519 to 0.717. Alpha coefficients for the internal 
consistency of factor scores ranged from 0.527 to 0.780. The split-half reliability for the scale 
was 0.793 (Chen, 2014). 
Anxious and depressive symptoms were measured using the HADS. The HADS is a 14-item 
self-rating scale that measures anxiety and depression, and is designed specifically for patients 
with physical illnesses. A score equal to or greater than 11 indicates ‘probable’ psychological 
morbidity while a score of 8–10 indicates ‘possible’ psychological morbidity. The scale has 
been validated in Chinese patients (Wang, 1999: 223–226; Zigmond and Snaith, 1983). 
Immune functions were examined by testing the level of IgA, IgG, IgM and NK cells 
(CD16+CD56+) in the patients’ peripheral blood. It is considered promising to see an increase 
in levels of the four cell types. The patients’ peripheral blood was taken before and after the 
interventions. IgA, IgG and IgM were assessed by an enzyme-linked immunosorbent assay 
(ELISA)-based assay. NK cells (CD16+CD56+) were assessed by flow cytometry (FCM). Lab 
personnel were blinded for treatment assignment. 
Statistical analysis 
Analyses were performed using the IBM SPSS Statistics software application (version 23.0: 
IBM, Armonk, NY, USA). Quantitative data were described as mean and standard deviation 
and categorical data as absolute frequencies and percentages. 
Baseline demographic and clinical characteristics were tested by the chi-square test and the 
analysis of variance (ANOVA) to assess comparability between the groups. The statistical 
analyses were considered bilateral and p < 0.05 was considered significant. 
The outcome variables and the difference value of the outcome variables for each group were 
compared between baseline and 2 weeks later by the ANOVA, and mixed ANOVA (between 
three groups and two time points) for this data. The differences of the outcome variable between 
baseline and 2 weeks later of each group, and the differences of the outcome variables between 
ICMT group and the control group, GCMT group and the control group and ICMT and GCMT 
groups were compared by Student–Newman–Kueuls test. Pearson correlation was employed to 
probe the impact factors of the changes of immune function. 
Results 
Comparisons for baseline characteristics of ICMT group, GCMT group and control group 
Table 1 presents characteristics of the participants. There were no significant differences among 
the three groups on baseline demographics. Within same stage cancer patients, there were also 
no differences between conditions on medical variables. 
Psychosomatic status, anxious and depressive symptoms 
There were no statistically significant differences among the ICMT group, GCMT group and 
the control group at baseline for all scores of PSSCP and HADS (Table 2). 
Compared with the control group, both the ICMT group and GCMT group showed significantly 
lower scores on all four dimensions of the PSSCP after the interventions, while the control 
group had significantly higher scores of somatic and social dimensions and no significant 
changes on other dimensions after 2 weeks. 
Anxiety and depression scores measured using the HADS were reduced significantly after the 
interventions in both treatment groups. No significant changes in anxiety and depression were 
observed in the control group. 
Compared with the control group, the ICMT group and GCMT group both scored significantly 
lower on all dimensions of PSSCP and HADS after the intervention. However, there were no 
significant differences between the two treatment groups by least significant difference (LSD) 
pairwise comparison. The mean values of difference between baseline and 2 weeks later of 
PSSCP and HADS in both intervention groups were significantly greater than in the control 
group. However, there were no significant differences between the two treatment groups. 
Immune functions: levels of IgA, IgG, IgM, NK cells 
Immune function variables did not differ significantly between the study groups at baseline. 
The mean level of IgG cells was significantly increased in the GCMT group and significantly 
decreased in the control group. The mean level of NK cells (CD16+CD56+) significantly 
decreased in the control group. The control group had significantly lower mean levels of IgG 
and NK cells than the intervention groups after 2 weeks. However, there were no significant 
differences between the two treatment groups by LSD pairwise comparison. The mean level of 
IgA and IgM cells had no significant change across the three groups. The average difference 
between baseline and 2 weeks later of the mean level of IgG and NK cells of both intervention 
groups were significantly different to the control group. However, there were no significant 
differences between the two treatment groups (Table 3). 
Immune functions and emotional, psychosomatic status 
A Pearson correlation of the changes from baseline between immune functions and PSSCP and 
HADS scores was conducted to probe the possible mechanism behind the effect. The result 
showed that changes in the mean level of IgG cells was significantly correlated to the changes 
of psychological, somatic, social state, psycho-behavioural resilience and anxiety and 
depression symptoms (Table 4). 
Discussion 
Our study suggests that using both ICMT and GCMT for advanced lung cancer patients results 
in significant improvements in emotional and psychosomatic status, and also in immune 
functions as observed through an increase in the presence of IgG and NK cells. The analysis of 
all the functioning dimensions of PSSCP and HADS revealed a significant improvement in both 
the ICMT group and the GCMT group after the interventions, though the magnitude of the 
effect did not differ significantly between the two intervention conditions. IgG cell levels 
increased significantly 2 weeks after the intervention in the GCMT group and decreased in the 
control group. NK cell activity decreased significantly in the control group after 2 weeks, but 
there were no significant changes between the two intervention groups. 
The results suggest that both ICMT and GCMT could be useful to regulate the emotional and 
psychosomatic adaptation process to the multiple challenges that the patients must face during 
cancer diagnosis and treatment. The treatments may improve patients’ anxious and depressive 
symptoms and psychosomatic state directly, or work to trigger their understanding and insight 
to achieve such improvements. These results are supported by systematic reviews and meta-
analyses that confirmed psychological interventions improved depression, anxiety, coping, 
adjustment, functional ability and quality of life (Badr et al., 2015; Graves, 2003; Osborn et al., 
2006; Williams and Dale, 2006). This study advances the knowledge of a new psychotherapy, 
MT. MT was developed to absorb the essences of two religions, Zen and Dao in particular. It 
focuses on raising clients’ insights into and understanding of life and restructuring their 
cognitive habits and modifying their behavioural mode towards becoming enterprising and 
optimistic, which appears to lead to a magnanimous and peaceful state of mind. It appears that 
MT can help patients to face and accept personal suffering (including death) peacefully, which 
demonstrates the advantages of MT compared with other psychotherapies. 
The participants received MT every day or every other day for 2 weeks. It appears that the 
intensive input strengthened the effects of MT, and served as an immersive experience for the 
participants. The characteristics of the MT content have been designed to not only raise insights 
and enlightenments, but also to be entertaining, thought-provoking and interesting. For example, 
therapists used short stories showed in animation to make the patients to understand death as 
another form of life (or entering the paradise). This appeared to make participants being less 
scared and desperate, which led to increased emotional wellbeing. Receiving MT appeared to 
make patients peaceful and relaxed. Furthermore, the results of pre- and post-tests of blood 
pressure, heart rate and respiratory rate showed that all these physiological indexes decreased 
significantly after MT, which suggests that MT could help the patients become more 
physiologically relaxed. In their reviews at the end of each MT session, patients often reported 
that they learnt a great deal from MT and felt much better after receiving the therapy, and that 
above all the experience and effects were enjoyable. Considering this, it is not surprising that 
MT appears to improve depression, anxiety and psychosomatic state in a 2-week period. The 
statistically significant findings illustrated in this study were observed during an extensively 
challenging period of one’s life, and after being diagnosed with one of the most severe and 
dangerous illnesses – advanced lung cancer. Clearly, bringing about changes in the patients’ 
emotional state at this time when they are facing death is of immense value. This premise is 
supported by other studies (Badr et al., 2015; Gordon et al., 2011; Hulbert-Williams at al., 
2015, Huang et al., 2019; Wahbeh et al., 2009). 
Aside from the observed psychological benefits of MT, the authors were very encouraged by 
the observed improvement in immune functions. Although some changes between groups that 
emerged in the trials did not seem remarkable before analysis, they were shown to be 
statistically significant under the study’s strict design and operation. For example, there were 
no observed changes in the levels of NK cells in the blood tests during a period of 2 weeks in 
the intervention groups, but there was a statistically significant reduction in the control group. 
This result implies that MT could help patients to avoid the reduction in the levels of NK cell 
function. These findings are of clinical significance, and are supported by other studies (Barry 
et al., 2016; Takashi and Yoko, 2003). It can be speculated that psychotherapy takes effect on 
immune functions through psychoneuroimmune pathways (Boggero and Segerstrom, 
2016; Evans et al., 2000; Schedlowski, 1999). It has been shown that psychotherapy improved 
mental state before it improved immune functions (Barry at al., 1988; Boggero and Segerstrom, 
2016; Evans et al., 2000; Schedlowski, 1999). Our Pearson correlation analysis of the changes 
from baseline and 2 weeks later of the indicators for the study groups showed that the 
improvements of emotional and psychosomatic status may be the factors that drive the 
improvements of IgG and NK cell levels. In other words, positive changes of IgG and NK cell 
levels might be mediated by the efficacy on anxious and depressive symptoms and psychosocial 
status. 
In their review on reviews on psychological interventions for distress in cancer 
patients, Lepore and Coyne (2006) suggested that the literature during the period between 
January 1995 and July 2005 do not provide conclusive support to the effectiveness of 
psychological interventions for cancer patients. However, this study makes a compelling case 
for the value of MT for advanced lung cancer patients. This is demonstrated in both physical 
and psychological outcomes of the significant improvements in the participating patients’ 
emotional and psychosomatic status, and their immune functions resulting in an increase in the 
presence of IgG and NK cells. 
Following the recommendations of Newell and the Revised Consort Statement (Moher et al., 
2001; Newell et al., 2002), the authors have clearly detailed the procedure of this study in the 
‘Study design’ section and have made significant efforts to control the impacts of the study, and 
have accounted for all patients’ disposition and clinical characteristics. In addition, the authors 
have included up to 30 patients per treatment arm, with a follow-up period. The types of 
interventions and the number of sessions have been described above. The study design has 
passed the examinations of oncologists, statisticians, other psychologists and psychiatrists, and 
was considered to be scientifically rigorous. 
Clinical implications 
This study represents the first controlled clinical study to assess the effectiveness of ICMT and 
GCMT on measures of psychosomatic status, anxiety and depression symptomatology; and 
immune functions among advanced lung cancer patients. The study revealed that both 
interventions could modulate emotion arousal and mind–body–immune interactions, which is 
crucial in the field of oncology (Barry et al., 1988; Gordon et al., 2011; Wahbeh et al., 2009). 
Study limitations 
There are several limitations to this study. First, this study only showed the short-term effects 
of ICMT and GCMT. Further research is warranted to assess both long-term and short-term 
effects. Second, the mechanism of the improvements of IgG and NK cell functions for MT 
needs further investigation. It is unclear why MT appeared to improve the IgG and NK cell 
functions but not the IgA and IgM cell functions. Third, this study aimed to examine the 
differences between the effects of ICMT and GCMT to distinguish their applications, but no 
significant differences were found. It might be that there is in fact no difference, or the non-
significance was caused by the small sample size of each GCMT group with three patients in 
each group. The effect differences between ICMT and GCMT warrant further exploration. 
Conclusion 
The authors have demonstrated that both ICMT and GCMT can have beneficial short-term 
effects on emotional, psychosomatic and immune function for advanced lung cancer patients. 
The improvements of immune functions may be correlated to the improvements of emotional 
and psychosocial status. Moreover, ICMT and GCMT seem to be equally beneficial. Following 
these promising results, further studies are being conducted with larger samples to better 
understand both the long-term and short-term biopsychosocial efficacy and mechanisms 
provided by ICMT and GCMT. 
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Table 1. Baseline characteristics of study participants 
 
Characteristic ICMTG (n=40) GCMTG (n=36) CTRLG (n=40) F/X² P  
Age -yr. Mean(SD) 
Male Sex, n(%) 




Education, N (%) 
Primary school 
Secondary school 
High school/Technical school 
University degree or higher 






Pathological diagnosis, N (%) 
 Squamous cell carcinoma 
 Adenocarcinoma 
 Adenosquamous cell carcinoma 
 Small cell carcinoma 
Stage of cancer, N (%) 
III 
 59.0(9.80) 
   26(65.0)  
 
   35(87.5) 











































    12(33.3) 
   59.7(10.7) 
26(65.0) 
    
35(87.5) 
 2(5.0) 




































































Type of treatment 
 Chemotherapy 
 Radiotherapy 




   10(25.0) 





















Table 2 Means and standard deviations of PSSCP and HADS at baseline and post-intervention  
compared with the 3 groups 
 





2 Weeks later 
t 
P 
d ±s (Change from baseline) 
   9.55(2.26) 
   8.20(1.59) 
   3.857 
   <0.001 
   1.35(2.21) 
   9.61(2.02) 
   8.06(1.47) 
   3.877 
   <0.001 


















2 Weeks later 
t 
P 
d ±s (Change from baseline) 
  8.48(1.96) 
  7.68(1.35) 
  2.667 
  0.011 
  0.80(1.90) 
   8.53(2.02) 
   7.81(1.12) 
   2.032 
   0.049 


















2 Weeks later 
t 
P 
d ±s (Change from baseline) 
   9.93(2.32) 
   9.23(2.01) 
   2.070 
   0.045 
   0.70 (2.14) 
  10.64(2.47) 
   9.08(1.87) 
   2.991 
   0.005 






















2 Weeks later 
t 
P 
d ±s (Change from baseline) 
   8.90(2.06) 
   8.10(2.38) 
   2.210 
   0.033 
   0.80(2.29) 
   9.33(1.94) 
   8.03(2.44) 
   2.366 
   0.024 

























     6.69(2.12) 
     5.19(1.47) 
     3.631 
  6.75(2.31) 
  6.90(2.13) 








d ±s (Change from baseline) 
<0.001 
1.45(1.28) 
    <0.001 
     1.50(2.48) 
  0.628 








2 Weeks later 
t 
P 
d ±s (Change from baseline) 
     9.13(2.53) 
     6.93(2.30) 
     9.242 
     <0.001 
     2.20(1.51) 
     9.50(2.49) 
     7.11(2.31) 
     4.280 
     <0.001 
     2.39(3.35) 
 10.08(2.15) 
 10.53(2.20) 
















2 Weeks later 
t 
P 











  16.83(3.37) 
  17.43(3.01) 
  -1.257 
  0.216 











d ±s (2wsL-B): the means of difference between baseline and 2 weeks later and deviations. 
  
Table 3. Means and standard deviations of the level of immune functions at baseline and post-
intervention compared with the 3 groups 
 
  ICMTG(n=40) GCMTG(n=36) CTRLG(n=40)   F P 
IgA 
Baseline 
2 Weeks later 
t 
P 
d ±s (Change from baseline) 
   2.84(1.13) 
  2.79 (1.16) 
  0.613 
  0.543 
  - 
 
  2.63(1.16) 
  3.02(1.49) 
  -1.232 
  0.226 


















2 Weeks later 
t 
P 






























2 Weeks later 
t 
P 
d ±s (Change from baseline) 
  0.99(0.66) 
  0.97(0.67) 
  0.346 
  0.731 
  - 























2 Weeks later 
t 
P 
d ±s (Change from 
baseline) 
  16.78(10.44) 
  19.21(10.73) 
  -1.900 
  0.065 
  -2.43(8.09) 
   
  13.71(7.74) 
  15.04(6.80) 
  -0.993 
  0.327 
  -1.33(8.06) 

















Table 4 Pearson correlation between the changes of immune functions and emotional, psychosomatic 
status 
 





  0.006 
  0.929 
   0.307 









  0.356 
   -0.168 








  0.031 
  0.642 
   0.327 










  0.845 



























   0.276 
   0.016 
  
   0.270 
   0.018 
 
-0.071 
 0.282 
 
-0.056 
 0.393 
  
 0.146 
 0.026 
 
 0.036 
 0.586 
 
 
 
  
 
 
 
 
 
 
 
